Diaphragmatic Thickness and Pulmonary Function in Parkinson's Disease
Correlation of Diaphragmatic Thickness With Pulmonary Function in Parkinson's Disease
1 other identifier
observational
37
1 country
1
Brief Summary
Ultrasound can give important information about the morphology of the diaphragm and the amount of contraction. Our aim, with the prediction that a restrictive pathology will occur in the pulmonary function with the addition of camptocormia in Parkinson's patients; to compare respiratory functions in Parkinson's patients with and without camptocormia, to investigate the correlation between ultrasonographically measured diaphragmatic thickness and pulmonary function test values.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 24, 2021
CompletedFirst Submitted
Initial submission to the registry
January 4, 2022
CompletedFirst Posted
Study publicly available on registry
January 18, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
February 15, 2023
CompletedApril 26, 2024
April 1, 2024
1 year
January 4, 2022
April 25, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Pulmonary function test
When the patient is in the suIt will be evaluated by conventional spirometric measurements. Pulmonary function tests will be applied to all individuals in a sitting position with the "Vmax Encore PFT system, Carefusion, CA USA" brand test device. In each measurement, the maneuvers will be repeated at least 3 times and the best values will be recorded. Forced vital capacity (FVC), expire in the first second of forced expiration (FEV1), and the ratio of FEV1 to FVC (FEV1/FVC) will be recorded.pine position, by placing a transducer on the chest wall at the level of the right 9th intercostal space, diaphragmatic movement will be monitored during inspiration, and diaphragmatic thickness will be measured at the end of expiration and inspiration. Thrombus location was evaluated proximal and/or distally by performing Doppler ultrasound
1 hour
Ultrasonography
When the patient is in the supine position, by placing a transducer on the chest wall at the level of the right 9th intercostal space, diaphragmatic movement will be monitored during inspiration, and diaphragmatic thickness will be measured at the end of expiration and inspiration. Thrombus location was evaluated proximal and/or distally by performing Doppler ultrasound
1 hour
Secondary Outcomes (1)
Camptocormia measurement
1 hour
Study Arms (2)
camptocormia group
Diaphragmatic thickness will be measured by ultrasonography. Respiratory function will be evaluated by spirometric measurements. Postural deviations of the spine, knees, and hips will be recorded through photographs taken from the side and back
no camptocormia group
Diaphragmatic thickness will be measured by ultrasonography. Respiratory function will be evaluated by spirometric measurements. Postural deviations of the spine, knees, and hips will be recorded through photographs taken from the side and back
Interventions
No intervention, observational only
Eligibility Criteria
Individuals diagnosed with Parkinson's Disease in our clinic between June 2021 and January 2023.
You may qualify if:
- Being diagnosed with Parkinson's
- Volunteer to participate in the study
You may not qualify if:
- Being in contact with or suffering from COVID-19
- Having diseases that increase intra-abdominal pressure and venous insufficiency
- Having diseases that affect diaphragmatic motility
- Have had recent thoracic or abdominal surgery
- Having a parenchymal, pleural, or chest wall mass that may cause restriction on a recent chest X-ray or CT
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Abant Izzet Baysal University Faculty of Health Science
Bolu, 14100, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ramazan Kurul, Ph.D
Abant Izzet Baysal University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Day
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
January 4, 2022
First Posted
January 18, 2022
Study Start
December 24, 2021
Primary Completion
January 1, 2023
Study Completion
February 15, 2023
Last Updated
April 26, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share